Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07288216 · ClinicalTrials.gov registry record · Phase 2
Transition to KPL-387 Monotherapy Dosing & Administration Study
A Phase 2 study of Heart Diseases and Recurrent Pericarditis, sponsored by Kiniksa Pharmaceuticals International.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 6
- Study locations
NCT07288216: Recruiting Phase 2 study of Heart Diseases and Recurrent Pericarditis, sponsored by Kiniksa Pharmaceuticals International.
NCT07288216 is a Phase 2 study of Heart Diseases and Recurrent Pericarditis that is actively recruiting participants, run by Kiniksa Pharmaceuticals International. The registered enrollment target is 80 participants, below the 5,531-participant average among 85 other Heart Diseases trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07288216, a Phase 2 study of Heart Diseases and Recurrent Pericarditis, is actively recruiting participants, sponsored by Kiniksa Pharmaceuticals International.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 6
- Study locations
Study Summary
The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.
Conditions Studied
Interventions
- DRUG KPL-387
Study Locations (6)
Texas
- Investigational Site 005 - Austin
- Investigational Site 006 - Houston
Virginia
- Investigational Site 004 - Charlottesville
- Investigational Site 001 - Norfolk
California
- Investigational Site 002 - Santa Monica
New York
- Investigational Site 003 - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-01-31 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
What NCT07288216 shows while recruiting
NCT07288216 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 5,531-participant average among 85 other Heart Diseases trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Heart Diseases appearing as the primary indexed condition, and to 1 intervention - of which KPL-387 is the first listed.
NCT07288216 lists 6 locations in 4 states (Texas, Virginia, California).
Frequently Asked Questions
What is clinical trial NCT07288216 about?
NCT07288216 is a clinical study titled "Transition to KPL-387 Monotherapy Dosing & Administration Study". The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.
What is the current status of trial NCT07288216?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2026-01-31. Estimated completion is 2029-12-31.
What conditions does trial NCT07288216 study?
This clinical trial studies the following conditions: Heart Diseases, Recurrent Pericarditis, Pericarditis.
What interventions are being tested in trial NCT07288216?
The interventions under investigation include: KPL-387 (DRUG).
Who is sponsoring clinical trial NCT07288216?
This trial is sponsored by Kiniksa Pharmaceuticals International, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07288216 being conducted?
This trial has 6 study locations across California, New York, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07288216's enrollment target sits among peer trials
80 71st of 85 higher than 15 of 85 other Heart Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women
RECRUITING · Phase 2
-
Effects of Resistance and Aerobic Exercise on Cardiovascular Health
COMPLETED · Phase 2
-
Effects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery
COMPLETED · Phase 2
-
A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
COMPLETED · Phase 2
-
Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent
COMPLETED · Phase 2
-
Estrogen, HDL, and Coronary Heart Disease in Women
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI